Cytek Biosciences (CTKB) Competitors $4.13 +0.10 (+2.58%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTKB vs. TXG, TRNS, EYPT, ALNT, AEHR, LAB, SENS, QTRX, QSI, and FEIMShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Aehr Test Systems (AEHR), Standard BioTools (LAB), Senseonics (SENS), Quanterix (QTRX), Quantum-Si (QSI), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry. Cytek Biosciences vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Allient Aehr Test Systems Standard BioTools Senseonics Quanterix Quantum-Si Frequency Electronics 10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Do analysts rate TXG or CTKB? 10x Genomics presently has a consensus target price of $13.54, indicating a potential downside of 3.28%. Cytek Biosciences has a consensus target price of $5.60, indicating a potential upside of 35.46%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38Cytek Biosciences 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has better earnings & valuation, TXG or CTKB? Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.82-$182.63M-$0.70-20.00Cytek Biosciences$200.45M2.62-$6.02M-$0.05-82.68 Is TXG or CTKB more profitable? Cytek Biosciences has a net margin of -3.27% compared to 10x Genomics' net margin of -13.13%. Cytek Biosciences' return on equity of -1.66% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Cytek Biosciences -3.27%-1.66%-1.30% Which has more risk & volatility, TXG or CTKB? 10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Do insiders and institutionals believe in TXG or CTKB? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Comparatively, 10.3% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer TXG or CTKB? In the previous week, 10x Genomics had 24 more articles in the media than Cytek Biosciences. MarketBeat recorded 35 mentions for 10x Genomics and 11 mentions for Cytek Biosciences. 10x Genomics' average media sentiment score of 0.63 beat Cytek Biosciences' score of 0.03 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 8 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Summary10x Genomics beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.78M$3.08B$5.62B$9.81BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-82.5020.5030.1625.63Price / Sales2.62363.33463.14174.62Price / Cash109.2140.7837.7258.50Price / Book1.397.698.456.05Net Income-$6.02M-$54.75M$3.26B$265.11M7 Day Performance6.27%3.51%3.20%2.55%1 Month Performance19.83%11.04%5.63%3.62%1 Year Performance-22.73%12.94%42.63%26.43% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences2.5534 of 5 stars$4.13+2.6%$5.60+35.5%-22.9%$524.78M$200.45M-82.50500News CoverageTXG10x Genomics3.8851 of 5 stars$13.68+4.6%$13.23-3.3%-34.8%$1.61B$610.78M-10.521,240News CoverageEarnings ReportAnalyst ForecastTRNSTranscat3.2584 of 5 stars$74.80+0.3%$112.20+50.0%-28.3%$694.69M$278.42M47.951,245News CoveragePositive NewsEarnings ReportAnalyst RevisionEYPTEyepoint Pharmaceuticals1.8025 of 5 stars$10.06+3.6%$25.67+155.1%+28.6%$668.16M$43.27M-4.17120Earnings ReportALNTAllient1.8461 of 5 stars$39.67+4.3%$31.00-21.9%+120.4%$643.64M$516.06M67.242,525Earnings ReportDividend AnnouncementAEHRAehr Test Systems1.5223 of 5 stars$19.03+13.0%N/A+47.9%$503.77M$58.97M-146.3790Positive NewsGap UpLABStandard BioTools2.1056 of 5 stars$1.32+1.5%$2.50+89.4%-17.6%$493.77M$174.43M-3.77620News CoveragePositive NewsAnalyst DowngradeSENSSenseonics2.0517 of 5 stars$0.51+3.9%$1.55+205.2%+22.9%$332.21M$23.68M-3.9190News CoverageAnalyst RevisionQTRXQuanterix2.0431 of 5 stars$6.04+3.1%$13.50+123.5%-57.8%$292.73M$137.42M-4.65460News CoverageEarnings ReportAnalyst ForecastQSIQuantum-Si2.7253 of 5 stars$1.44-1.4%$3.48+141.3%+39.7%$267.91M$3.06M-2.12150Gap UpFEIMFrequency Electronics1.4661 of 5 stars$27.73+4.8%N/A+150.9%$257.30M$69.81M11.23200 Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Allient Alternatives Aehr Test Systems Alternatives Standard BioTools Alternatives Senseonics Alternatives Quanterix Alternatives Quantum-Si Alternatives Frequency Electronics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTKB) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access